May 17, 2020

A way to increase the R&D in drug companies

Admin
3 min
A way to increase the R&D in drug companies.jpg
Written by Alyssa Clark It is no secret that the journey from an idea to a full-blown, FDA approved drug is an expensive and lengthy process. For phar...

Written by Alyssa Clark

 

It is no secret that the journey from an idea to a full-blown, FDA approved drug is an expensive and lengthy process. For pharmaceutical startups, this feat seems nearly impossible and cannot be completed without tons of federal research grants or a partner to funnel the money for development. On average, this process can take anywhere upwards of 15 years and costs close to a billion dollars, just to get it off the ground and running. With these kinds of odds and the heavy investments necessary for take-off, it’s no wonder why pharmaceutical companies everywhere are constantly looking for new ways of cost-effective R&D.

Recently, companies have been trying to combat this problem by forming packs with larger organizations like the NIH. In a five-year collaboration, the NIH and ten drug companies entered into a formal collaboration called the Accelerating Medicines Partnership. The NIH and these ten companies committed to sharing scientists, blood and tissue samples and data in order to better understand the disease process of Alzheimer’s, rheumatoid arthritis, Type 2 diabetes and lupus. The reasoning behind gaining access to this now shared information, is in hopes of assessing better drug targets and that this will lead to new experimental drugs with a higher chance for a success rate.

Partnerships, like the one with the NIH, show great initiative and will hopefully lead to future collaborations for drug companies around the world. However, a downside to this idea is that it only helps early on in the process, with ideal target and selection. This means that the company still needs to be able to find and identify an appropriate compound that produces successful results and does so safely at that. Long-term, the knowledge gained by and shared by the AMP will benefit all parties, but it will only impact R&D efforts in its earliest stages. This calls for more improvements to be made along the rest of the process, and to not settle for an easy-fix for the drug companies.

The next arena that is being called into questions by pharma R&D analysts, is that of the clinical trial process. Forbes magazine pulled an example of how to improve the clinical trial steps of the process, from an article in Nature Biotechnology. John LaMattina from Forbes writes, “Entitled ‘Clinical development success rates for investigational drugs’, the authors have provided a comprehensive study of clinical success rates across the drug industry. They have analyzed 2003 – 2011 data from 835 companies including large pharma/biotech, small to mid-sized pharma/biotech, and emerging biotech. Their data set includes 4,451 drugs with 7,372 independent clinical development paths (the larger number of the latter is due to companies exploring a single compound for multiple indications such as for different types of cancer). They have analyzed the data in many ways, including survival rates by therapeutic area, by molecule type (small versus biologicals) and by lead or non-lead indication. For a drug R&D aficionado, the data are fascinating.”

By improving the initial stages of R&D with partnerships with organizations like the NIH and with investing time and effort into the clinical trial stage of data, big pharma companies can begin to see an improvement in their R&D process, as well as pay-offs from restructuring this sometimes ineffective process. Even if it means cutting a year or two out of the 15-20 year process, those years could be well-spent earning back the companies’ initial investments, instead of continuing to prolong the experimental and nonearning period of R&D. 

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article